Press Releases

Search Press Releases:

• All News
• 2019
• 2018
• 2017
• 2016
• 2015
• 2014
• 2013
• 2012
• 2011
• 2010

Tonix Pharmaceuticals Prices $9.0 Million Public Offering

November 15, 2019 • 8:30 AM EST

Tonix Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

November 8, 2019 • 4:45 PM EST

Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya® for PTSD, Following FDA Meeting

November 4, 2019 • 7:00 AM EST

Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split

October 31, 2019 • 1:00 PM EDT

Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX-601

October 23, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Joins the Alliance for Biosecurity

October 15, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Announces that the European Patent Office Opposition Division Has Upheld Its Patent for the Use of the Active Ingredient in TNX-102 SL, Cyclobenzaprine, for the Treatment of PTSD

October 7, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Announces Completion of Long-Term Exposure Studies in Participants with PTSD to Evaluate the Tolerability of TNX-102 SL 5.6 mg

October 3, 2019 • 8:00 AM EDT

Tonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreatic Cancers

September 16, 2019 • 4:15 PM EDT

Tonix Pharmaceuticals Announces Publication of Paper on Triple Reuptake Inhibitor TNX-1600 (formerly D-578) in the European Journal of Pharmacology

September 16, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals to Speak at the 2019 Annual National Association of Veterans’ Research and Education Foundations (NAVREF) Conference

September 12, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences

September 10, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Doses Participants in Phase 1 Study Evaluating TNX-601 for the Daytime Treatment of Posttraumatic Stress Disorder

September 4, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals and Massachusetts General Hospital Enter into Research Collaboration to Develop Tonix’s Third Generation Anti-CD154 Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Organ Transplant Rejection

August 21, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Expands Preclinical Pipeline with Triple Reuptake Inhibitor, TNX-1600, for the Treatment of PTSD

August 20, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights

August 12, 2019 • 8:00 AM EDT

Tonix Pharmaceuticals Announces Director Stepping Down

August 2, 2019 • 4:05 PM EDT

Tonix Pharmaceuticals Announces Issuance of U.S. Patent for the Composition and Formulation of TNX-102 SL

July 25, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Announces Closing of Public Offering of Common Stock

July 18, 2019 • 4:05 PM EDT

Tonix Pharmaceuticals Announces Pricing of Public Offering of Common Stock

July 16, 2019 • 8:30 AM EDT

Tonix Pharmaceuticals Announces Issuance of Patent in China for the Composition and Formulation of TNX-102 SL

June 13, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Presented Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology

May 30, 2019 • 8:00 AM EDT

Tonix Pharmaceuticals to Present at BIO 2019 International Convention

May 28, 2019 • 4:15 PM EDT

Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication

May 23, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals to Speak at the Second Chance Digital Impact Recipient Gala

May 22, 2019 • 4:19 PM EDT

Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology

May 21, 2019 • 4:15 PM EDT

Tonix Pharmaceuticals Announces Director Stepping Down

May 17, 2019 • 4:05 PM EDT

Tonix Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights

May 13, 2019 • 8:00 AM EDT

Tonix Pharmaceuticals Announces New Board Member, Daniel Goodman, M.D., MBA

May 8, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Announces Update on the Collaborative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA)

April 23, 2019 • 1:51 PM EDT

Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya® for the Treatment of Posttraumatic Stress Disorder

April 22, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia

April 4, 2019 • 7:30 AM EDT

Tonix Pharmaceuticals to Present at Upcoming Investor Conferences

March 25, 2019 • 8:00 AM EDT

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights

March 18, 2019 • 8:00 AM EDT

Tonix Pharmaceuticals to Participate at Upcoming Investor Conferences

March 12, 2019 • 7:30 AM EDT

Tonix Pharmaceuticals Enrolls First Participant in the “RECOVERY” Study -- a New Phase 3 Trial of Tonmya® for the Treatment of Posttraumatic Stress Disorder

March 11, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Announces New European Use Patent for TNX-601

March 7, 2019 • 4:15 PM EST

Tonix Pharmaceuticals Provides Update on Tonmya® for the Treatment of Posttraumatic Stress Disorder

March 1, 2019 • 5:41 PM EST

Tonix Pharmaceuticals Announces Share Repurchase Program

March 1, 2019 • 4:00 PM EST

Tonix Pharmaceuticals Announces New Board Member, James Treco

February 19, 2019 • 4:30 PM EST

Tonix Pharmaceuticals to Present at BIO CEO & Investor Conference

February 4, 2019 • 8:00 AM EST

Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion

January 2, 2019 • 7:00 AM EST

Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement

December 18, 2018 • 7:00 AM EST

Tonix Pharmaceuticals Announces Closing of $15,000,000 Public Offering

December 11, 2018 • 4:00 PM EST

Tonix Pharmaceuticals Prices $15,000,000 Public Offering

December 7, 2018 • 10:35 AM EST

Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes

November 29, 2018 • 7:00 AM EST

Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split

November 27, 2018 • 7:00 AM EST

Tonix Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights

November 9, 2018 • 7:30 AM EST

Tonix Pharmaceuticals Announces New Patent Coverage Protecting Tonmya®

November 7, 2018 • 7:00 AM EST

Tonix Pharmaceuticals Presented Results and Retrospective Analyses of Phase 3 P301 “HONOR” Study in Poster Presentation at CNS Summit 2018

November 6, 2018 • 7:00 AM EST

Tonix Pharmaceuticals to Present at BIO-Europe International Partnering Conference

November 1, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Announces Innovative Design in Next Phase 3 Study of Tonmya® for PTSD, Following FDA Meeting

October 31, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in Poster Presentations at CNS Summit 2018

October 29, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the Dawson James Securities Small Cap Growth Conference

October 23, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the MicroCap Conference

September 26, 2018 • 1:30 PM EDT

Tonix Pharmaceuticals to Present at Sidoti & Company Fall 2018 Investor Conference

September 20, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Announces New Board Member, Oye Olukotun, M.D.

September 7, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences

August 30, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Announces Director Stepping Down

August 22, 2018 • 4:01 PM EDT

Tonix Pharmaceuticals Presents Results and Retrospective Analyses of Two Double-Blind, Randomized Placebo-Controlled 12-Week Studies of Tonmya® in Military-Related PTSD at the 2018 Military Health System Research Symposium

August 21, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in a Poster Presentation at the 2018 Military Health System Research Symposium

August 15, 2018 • 11:46 AM EDT

Tonix Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights

August 13, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 HONOR Study of Tonmya® in Military-Related PTSD

July 27, 2018 • 8:00 AM EDT

Tonix Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for TNX-102 SL for Treatment of Agitation in Alzheimer’s Disease

July 16, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Presented New Data Related to Suicidal Ideation and Behaviors in Military-Related PTSD from the Phase 2 AtEase Study at the American Society of Clinical Psychopharmacology

May 31, 2018 • 4:30 PM EDT

Tonix Pharmaceuticals to Present at the 2018 BIO International Convention

May 30, 2018 • 8:00 AM EDT

Tonix Pharmaceuticals Reports Preliminary Results from a Phase 1 Pivotal Multiple-Dose Bridging Pharmacokinetic (PK) Study of Tonmya® or TNX-102 SL

May 24, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the 2018 American Society of Clinical Psychopharmacology

May 23, 2018 • 4:05 PM EDT

Tonix Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs Update

May 14, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the BIO KOREA 2018 International Convention

May 7, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Receives IND Clearance by U.S. FDA for TNX-102 SL in Agitation in Alzheimer’s Disease

May 1, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York

April 4, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD

April 3, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Expands Intellectual Property Portfolio for TNX-102 SL

March 21, 2018 • 4:05 PM EDT

Tonix Pharmaceuticals to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium

March 13, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Programs Update

March 12, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the 30th Annual ROTH Conference

March 6, 2018 • 7:00 AM EST

Tonix Pharmaceuticals Appoints David L. Grange to the Board of Directors

February 15, 2018 • 7:00 AM EST

Tonix Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor Conference in New York City

February 7, 2018 • 4:30 PM EST

Tonix Pharmaceuticals to Present at Noble Capital Markets’ Fourteenth Annual Investor Conference in Fort Lauderdale

January 24, 2018 • 4:30 PM EST

Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)

January 23, 2018 • 7:00 AM EST

Tonix Pharmaceuticals Announces Publication Reporting Synthesis, Construction and Characterization of a Potential Smallpox-Preventing Vaccine Candidate TNX-801 (Live Horsepox Virus from Cell Culture)

January 19, 2018 • 2:00 PM EST

Tonix Pharmaceuticals Appoints Jessica Morris as Chief Operating Officer

January 9, 2018 • 7:00 AM EST

Tonix Pharmaceuticals to Present at Sachs Associates Neuroscience Innovation Forum and Biotech Showcase 2018 in San Francisco

January 3, 2018 • 7:00 AM EST

Tonix Pharmaceuticals Completes Positive Pre-IND Meeting with FDA for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) as a Clinical Candidate for Agitation in Alzheimer’s Disease

December 12, 2017 • 7:00 AM EST

Tonix Pharmaceuticals to Present at 10th Annual LD Micro Investor Conference

November 30, 2017 • 7:00 AM EST

Tonix Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs Update

November 7, 2017 • 7:00 AM EST

Tonix Pharmaceuticals to Present at 23rd Annual BIO-Europe International Partnering Conference

November 1, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Reports Outcomes from U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) for PTSD

October 17, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference

October 12, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Presented at the 2nd Annual Cohen Veterans Care Summit in Washington, D.C.

September 29, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Receives European Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)

September 14, 2017 • 4:05 PM EDT

Tonix Pharmaceuticals Elects Margaret Smith Bell to the Board of Directors

September 14, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

September 6, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Presented Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing Phase 3 Trial at the 2017 Military Health System Research Symposium

August 29, 2017 • 4:30 PM EDT

Tonix Pharmaceuticals to Present Additional Phase 2 Clinical Results and Design of Ongoing Phase 3 Trial in Military-Related PTSD at the 2017 Military Health System Research Symposium

August 21, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Programs Update

August 14, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya® as Proposed Brand Name for TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD

July 6, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the 2017 BIO International Convention

June 16, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Participated in the "Pathophysiology of Posttraumatic Stress Disorder: Rethinking Drug Targets” Summit Sponsored by U.S. Department of Defense

June 15, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals to Present an Update of FDA Designated Breakthrough Therapy-TNX-102 SL for PTSD at the 2017 Marcum MicroCap Conference

June 12, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Presented Retrospective Analyses of Treatment Response and Remission to TNX-102 SL in a Phase 2 Military-Related PTSD Study

May 30, 2017 • 4:30 PM EDT

Tonix Pharmaceuticals to Present Additional Clinical Results of Military-Related PTSD Study at the 2017 American Society of Clinical Psychopharmacology Annual Meeting

May 24, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD

May 22, 2017 • 4:05 PM EDT

Tonix Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Programs Update

May 15, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals to Present PTSD Clinical Data at the Society of Biological Psychiatry 72nd Annual Scientific Convention

May 11, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-102 SL Composition and Formulation: Designed for Transmucosal Absorption and Bedtime Daily Use

May 2, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Programs Update

April 17, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option

April 13, 2017 • 11:30 AM EDT

Tonix Pharmaceuticals Reports Results from U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting on TNX-102 SL for Posttraumatic Stress Disorder

April 11, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Completes $8 Million Public Offering of Common Stock

April 4, 2017 • 11:30 AM EDT

Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement

April 3, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Prices Public Offering of 1,800,000 Shares of Common Stock

March 30, 2017 • 8:01 AM EDT

Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock

March 29, 2017 • 4:07 PM EDT

Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at The MicroCap Conference

March 29, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Enrolls First Participant in Military-Related PTSD Phase 3 Trial of FDA Breakthrough Therapy-Designated TNX-102 SL

March 28, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split

March 16, 2017 • 1:00 PM EDT

Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program at Oppenheimer’s 27th Annual Healthcare Conference

March 15, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent Covering Composition and Manufacture of TNX-102 SL

March 14, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the 29th Annual ROTH Conference

March 7, 2017 • 7:00 AM EST

Tonix Pharmaceuticals Announces Demonstrated Vaccine Activity in First-Ever Synthesized Chimeric Horsepox Virus

March 2, 2017 • 7:24 AM EST

Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the Cowen and Company 37th Annual Health Care Conference

February 28, 2017 • 7:00 AM EST

Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the 2017 BIO CEO & Investor Conference

February 9, 2017 • 7:00 AM EST

Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at NobleCon13

January 24, 2017 • 7:00 AM EST

Tonix Pharmaceuticals Presented Details of Newly Expanded Product Development Pipeline at 9th Annual Biotech Showcase Conference

January 10, 2017 • 1:00 PM EST

Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at 9th Annual Biotech Showcase Conference

January 3, 2017 • 7:00 AM EST

Tonix Pharmaceuticals’ PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation by the FDA

December 19, 2016 • 7:00 AM EST

Tonix Pharmaceuticals Presented New Clinical Results from Sub-Group Analysis of Phase 2 AtEase Study in Military-Related Posttraumatic Stress Disorder (PTSD)

December 8, 2016 • 7:00 AM EST

Tonix Pharmaceuticals to Present Clinical Data at the 55th Annual Meeting of the American College of Neuropsychopharmacology (ACNP)

December 2, 2016 • 7:21 AM EST

Tonix Pharmaceuticals to Present at 9th Annual LD Micro Main Event Investor Conference

November 30, 2016 • 7:00 AM EST

Tonix Pharmaceuticals Reports Third Quarter 2016 Financial Results

November 10, 2016 • 4:30 PM EST

Tonix Pharmaceuticals to Present New Clinical Results from Retrospective Analysis of Phase 2 AtEase Study in Military-Related PTSD

November 10, 2016 • 7:00 AM EST

Tonix Pharmaceuticals to Present Clinical Data at the International Society for Traumatic Stress Studies (ISTSS) 32nd Annual Meeting

November 7, 2016 • 7:00 AM EST

Tonix Pharmaceuticals to Present at 22nd Annual BIO-Europe® International Partnering Conference

November 2, 2016 • 7:00 AM EDT

Tonix Pharmaceuticals to Present Clinical Data at the 2016 Neuroscience Education Institute (NEI) Psychopharmacology Congress

November 1, 2016 • 4:30 PM EDT

Tonix Pharmaceuticals Completes $5.2 Million Underwritten Public Offering

October 31, 2016 • 4:30 PM EDT

Tonix Pharmaceuticals to Present Clinical Data at CNS Summit 2016

October 27, 2016 • 4:33 PM EDT

Tonix Pharmaceuticals Prices $5.2 Million Underwritten Public Offering

October 26, 2016 • 8:46 AM EDT

Tonix Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Warrants

October 25, 2016 • 5:15 PM EDT

Tonix Pharmaceuticals to Host Posttraumatic Stress Disorder (PTSD) Awareness Day

October 19, 2016 • 7:00 AM EDT

UPDATE -- Tonix Pharmaceuticals to Present at Dawson James Securities 2016 Small Cap Growth Stock Conference

October 18, 2016 • 5:48 PM EDT

Tonix Pharmaceuticals to Present at Dawson James Securities 2016 Small Cap Growth Stock Conference

October 13, 2016 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at 16th Annual Sachs Biotech in Europe Forum

September 26, 2016 • 9:00 AM EDT

Tonix Pharmaceuticals to Present at Rodman & Renshaw 18th Annual Global Investment Conference

September 7, 2016 • 7:39 AM EDT

Tonix Pharmaceuticals Reports Topline Results from Phase 3 AFFIRM Study of TNX-102 SL in Fibromyalgia and Provides Corporate Update

September 6, 2016 • 7:00 AM EDT

Tonix Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for TNX-102 SL in Post-Traumatic Stress Disorder

August 29, 2016 • 7:00 AM EDT

Tonix Pharmaceuticals Presents Poster on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2016 Military Health System Research Symposium

August 15, 2016 • 7:00 AM EDT

Tonix Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Programs Update

August 8, 2016 • 7:00 AM EDT

Tonix Pharmaceuticals Initiates Second Pivotal Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia

July 26, 2016 • 8:00 AM EDT

Tonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option

July 12, 2016 • 4:30 PM EDT

Tonix Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

July 7, 2016 • 4:05 PM EDT

Tonix Pharmaceuticals Completes $10 Million Public Offering of Common Stock

June 21, 2016 • 12:00 PM EDT

Tonix Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

June 17, 2016 • 8:00 AM EDT

Tonix Pharmaceuticals Prices Underwritten Public Offering of Common Stock

June 16, 2016 • 8:00 AM EDT

Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock

June 15, 2016 • 4:01 PM EDT

Tonix Pharmaceuticals Presents at EULAR Results of a Retrospective Analysis from the Phase 2b BESTFIT Clinical Study of TNX-102 SL in Fibromyalgia

June 9, 2016 • 10:30 AM EDT

Tonix Pharmaceuticals to Present at the 2016 BIO International Convention

June 3, 2016 • 7:00 AM EDT

Tonix Pharmaceuticals Presents Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) at the American Society of Clinical Psychopharmacology (ASCP) 2016 Annual Meeting

May 31, 2016 • 7:00 AM EDT

Tonix Pharmaceuticals to Present Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the ASCP 2016 Annual Meeting

May 26, 2016 • 8:30 AM EDT

Tonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD)

May 19, 2016 • 6:00 AM EDT

Tonix Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Programs Update

May 9, 2016 • 7:00 AM EDT

Tonix Pharmaceuticals Completes Enrollment in Phase 3 Clinical Trial of TNX-102 SL in Fibromyalgia

May 2, 2016 • 7:05 AM EDT

Tonix Pharmaceuticals to Present at the 10th Annual BIO Europe Spring Conference

March 29, 2016 • 7:00 AM EDT

Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting

March 9, 2016 • 7:00 AM EST

Tonix Pharmaceuticals to Present at the 28th Annual ROTH Conference

March 8, 2016 • 4:05 PM EST

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Programs Update

March 4, 2016 • 7:00 AM EST

Tonix Pharmaceuticals to Present at Two Investor Conferences in March 2016

March 3, 2016 • 7:00 AM EST

Tonix Pharmaceuticals Appoints Chief Financial Officer

February 25, 2016 • 4:05 PM EST

Tonix Pharmaceuticals Reports Top Line Results From Phase 2 Proof-of-Concept Clinical Study of TNX-201 in Episodic Tension-Type Headache

February 16, 2016 • 8:00 AM EST

Tonix Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference

February 2, 2016 • 7:05 AM EST

Tonix Pharmaceuticals Announces Management Change

January 8, 2016 • 4:05 PM EST

Tonix Pharmaceuticals to Present at Biotech Showcase 2016

January 5, 2016 • 7:00 AM EST

Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD)

December 23, 2015 • 7:00 AM EST

Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Study of TNX-201 in Episodic Tension-Type Headache

December 8, 2015 • 7:00 AM EST

Tonix Pharmaceuticals and U.S. Department of Defense Military Developer in Partnership to Expand Efforts to Examine TNX-102 SL for Post-Traumatic Stress Disorder

December 7, 2015 • 7:00 AM EST

Tonix Pharmaceuticals to Participate in Fireside Chat at the Oppenheimer 26th Annual Healthcare Conference

December 1, 2015 • 7:00 AM EST

Tonix Pharmaceuticals Presents Additional Data on Tonmya(TM) Demonstrating Improvements in Sleep, Pain, and Other Outcomes in Fibromyalgia at 2015 ACR/ARHP Annual Meeting

November 10, 2015 • 8:30 AM EST

Tonix Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Programs Update

November 9, 2015 • 7:00 AM EST

Tonix Pharmaceuticals Announces Acceptance of Three Abstracts to be Presented at the 2015 ACR/ARHP Annual Meeting

October 1, 2015 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the 15th Annual Biotech in Europe Forum for Global Partnering and Investment

September 24, 2015 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference

September 8, 2015 • 7:05 AM EDT

Tonix Pharmaceuticals Presents on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2015 Military Health System Research Symposium

August 18, 2015 • 1:00 PM EDT

Tonix Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Program Update

August 10, 2015 • 7:00 AM EDT

Tonix Pharmaceuticals Appoints Mark T. Edgar, PhD as Senior Vice President of Product Development

July 21, 2015 • 7:05 AM EDT

Tonix Pharmaceuticals Closes $20.1 Million Public Offering of Common Stock

July 17, 2015 • 12:00 PM EDT

Tonix Pharmaceuticals Prices Underwritten Public Offering of Common Stock

July 14, 2015 • 8:30 AM EDT

Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock

July 13, 2015 • 4:02 PM EDT

Tonix Pharmaceuticals Presents Non-clinical Data on TNX-201 at the 57th Annual Scientific Meeting of the American Headache Society

June 22, 2015 • 8:00 AM EDT

Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya as Proposed Brand Name for Cyclobenzaprine HCl Sublingual Tablets, 2.8 mg

June 17, 2015 • 7:15 AM EDT

Tonix Pharmaceuticals Initiates Phase 2 Clinical Study of TNX-201 in Episodic Tension-Type Headache

June 16, 2015 • 7:15 AM EDT

Tonix Pharmaceuticals Presents Additional Data From Phase 2b BESTFIT Clinical Study at EULAR

June 11, 2015 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference

May 28, 2015 • 8:40 AM EDT

Tonix Pharmaceuticals Announces Acceptance of Two Abstracts for Presentation at EULAR

May 26, 2015 • 3:45 PM EDT

Tonix Pharmaceuticals Presents Data at the Annual Meeting of the Society for Biological Psychiatry

May 15, 2015 • 9:00 AM EDT

Tonix Pharmaceuticals Launches Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia

May 13, 2015 • 6:00 AM EDT

Tonix Pharmaceuticals Reports First Quarter 2015 Financial Results and Clinical Update

May 11, 2015 • 6:00 AM EDT

Tonix Pharmaceuticals to Present at the 12th Annual BIO Asia International Conference

March 20, 2015 • 11:30 AM EDT

Tonix Pharmaceuticals to Present at the 27th Annual ROTH Conference

March 4, 2015 • 8:40 AM EST

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results

March 3, 2015 • 8:00 AM EST

Tonix Pharmaceuticals to Present at the 8th Annual European Life Sciences CEO Forum

March 2, 2015 • 8:40 AM EST

Tonix Pharmaceuticals Announces Closing of $28.7 Million Public Offering of Common Stock

February 9, 2015 • 1:45 PM EST

Tonix Pharmaceuticals to Present at the BIO CEO & Investor Conference

February 5, 2015 • 3:00 PM EST

Tonix Pharmaceuticals Prices Underwritten Public Offering of Common Stock

February 4, 2015 • 1:15 PM EST

Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock

February 3, 2015 • 9:02 PM EST

Tonix Pharmaceuticals Commences Phase 2 Trial of TNX-102 SL in Post-Traumatic Stress Disorder

January 15, 2015 • 7:00 AM EST

Tonix Pharmaceuticals to Present at the Noble Financial Annual Investor Conference

January 14, 2015 • 8:40 AM EST

Tonix Pharmaceuticals Announces Clinical Progress on Potential Treatment for Headache

January 9, 2015 • 7:00 AM EST

Tonix Pharmaceuticals Provides Clinical and Regulatory Update on its Continued Development of TNX-102 SL in Fibromyalgia

January 6, 2015 • 7:00 AM EST

Tonix Pharmaceuticals to Present at the LD Micro Investor Conference

November 25, 2014 • 8:40 AM EST

Tonix Pharmaceuticals Reports Third Quarter 2014 Financial Results

November 10, 2014 • 8:40 AM EST

Tonix Pharmaceuticals Receives IND Clearance for TNX-201 in Episodic Tension-Type Headache

October 21, 2014 • 8:40 AM EDT

Tonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial of TNX-102 SL in Patients With Fibromyalgia

September 29, 2014 • 6:00 AM EDT

Tonix Pharmaceuticals to Present at the BioCentury NewsMakers Conference

September 19, 2014 • 8:40 AM EDT

Tonix Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference

September 3, 2014 • 8:40 AM EDT

Tonix Pharmaceuticals Announces Transfer to the NASDAQ Global Market

August 11, 2014 • 8:40 AM EDT

Tonix Pharmaceuticals Reports Second Quarter 2014 Financial Results

August 8, 2014 • 4:05 PM EDT

Tonix Pharmaceuticals to Present at Two Investor Conferences in August

August 6, 2014 • 8:40 AM EDT

Tonix Pharmaceuticals Announces Registered Direct Offering of $7.8 Million

July 11, 2014 • 8:20 AM EDT

Tonix Pharmaceuticals Joins Russell Microcap Index

June 30, 2014 • 12:00 PM EDT

Tonix Pharmaceuticals Appoints Ronald R. Notvest, Ph.D. as Senior Vice President of Commercial Planning and Development

June 26, 2014 • 8:30 AM EDT

Tonix Pharmaceuticals Receives IND Clearance From U.S. Food and Drug Administration for TNX-102 SL in Post-Traumatic Stress Disorder

June 10, 2014 • 8:30 AM EDT

Tonix Appoints Gregory M. Sullivan, M.D. as Chief Medical Officer

June 3, 2014 • 9:00 AM EDT

Tonix Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference

May 29, 2014 • 8:40 AM EDT

Tonix Pharmaceuticals to Present at the LD Micro Invitational Conference

May 29, 2014 • 8:20 AM EDT

Tonix Pharmaceuticals to be Added to the MSCI Global Micro Cap Index

May 28, 2014 • 2:26 PM EDT

Tonix Pharmaceuticals to Present at the MIXiii Biomed Conference in Israel

May 20, 2014 • 8:40 AM EDT

Tonix Pharmaceuticals Reports First Quarter 2014 Financial Results

May 13, 2014 • 5:00 PM EDT

Tonix Pharmaceuticals Completes Enrollment in BESTFIT Trial of TNX-102 SL for Fibromyalgia

May 12, 2014 • 8:40 AM EDT

Tonix Pharmaceuticals Spotlighted in April 7 Issue of BioCentury

April 9, 2014 • 8:40 AM EDT

Tonix Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President, Clinical Development and Regulatory Affairs

April 1, 2014 • 8:45 AM EDT

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results

March 31, 2014 • 9:15 AM EDT

Tonix Pharmaceuticals to Present at the ROTH Conference

March 5, 2014 • 8:20 AM EST

Tonix Pharmaceuticals Completes Pre-IND Meeting With FDA on TNX-201 for Episodic Tension-Type Headache: Clinical Development to Begin in 4Q 2014

March 3, 2014 • 9:35 AM EST

Tonix Pharmaceuticals Spotlighted in Three Media Outlets in February

February 21, 2014 • 8:20 AM EST

Tonix Pharmaceuticals to Present at the BIO CEO Conference

February 4, 2014 • 8:40 AM EST

Tonix Pharmaceuticals Announces Closing of $43.5 Million Public Offering of Common Stock

January 29, 2014 • 11:15 AM EST

Tonix Pharmaceuticals Prices Underwritten Public Offering Raising $43.5 Million

January 24, 2014 • 8:20 AM EST

Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock

January 23, 2014 • 4:02 PM EST

Tonix Pharmaceuticals Announces the Enrollment of Completers From the BESTFIT Trial Into a 12-Month Open-Label Extension Study

December 10, 2013 • 8:40 AM EST

Tonix Pharmaceuticals to Present at the Oppenheimer Healthcare Conference

November 26, 2013 • 8:40 AM EST

Tonix Pharmaceuticals to Present at the LD Micro Conference

November 21, 2013 • 9:05 AM EST

Tonix Pharmaceuticals Reports Third Quarter 2013 Financial Results

November 13, 2013 • 4:05 PM EST

Tonix Pharmaceuticals Partners With the American Chronic Pain Association to Help Raise Awareness About Fibromyalgia

October 24, 2013 • 8:45 AM EDT

Tonix Pharmaceuticals to Participate in the Women's Healthcare Innovation and Leadership Showcase on October 15, 2013

October 11, 2013 • 9:27 AM EDT

Tonix Pharmaceuticals Initiates Enrollment in Phase 2b BESTFIT Trial of TNX-102 SL in Fibromyalgia Patients

September 16, 2013 • 8:01 AM EDT

Tonix Pharmaceuticals to Present at the First Global Life Sciences Conference in Warsaw, Poland on September 17, 2013

September 12, 2013 • 8:00 AM EDT

Tonix Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on September 9, 2013

September 4, 2013 • 8:00 AM EDT

Tonix Pharmaceuticals Presents Nonclinical Results at the Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome

August 19, 2013 • 8:00 AM EDT

Tonix Pharmaceuticals Announces Closing of Public Offering

August 14, 2013 • 12:30 PM EDT

Tonix Pharmaceuticals Announces Pricing of Public Offering of Units and NASDAQ Listing

August 9, 2013 • 8:35 AM EDT

Tonix Pharmaceuticals Announces Reverse Split of Common Stock

May 1, 2013 • 9:05 AM EDT

Tonix Pharmaceuticals to Hold Annual Shareholders' Meeting on April 19, 2013

April 11, 2013 • 8:05 AM EDT

TONIX Completes Pre-Phase 3 Meeting With U.S. Food and Drug Administration for TNX-102 SL in Fibromyalgia

March 11, 2013 • 7:56 AM EDT

Tonix Pharmaceuticals to Present at the SeeThruEquity MicroCap Investor Forum on March 12

March 8, 2013 • 7:55 AM EST

Tonix Pharmaceuticals to Present at Upcoming Conferences

February 5, 2013 • 8:00 AM EST

Tonix Pharmaceuticals Completes $1 Million Financing With Technology Partners

December 27, 2012 • 8:00 AM EST

Tonix Pharmaceuticals Completes Private Placement

December 5, 2012 • 8:36 AM EST

Tonix Pharmaceuticals to Present at Fifth Annual LD Micro Conference

December 5, 2012 • 8:33 AM EST

Tonix Pharmaceuticals Completes Convertible Note Offering

November 14, 2012 • 4:15 PM EST

Tonix Pharmaceuticals Presents Research Findings at the 2012 American College of Rheumatology Annual Scientific Meeting

November 13, 2012 • 8:00 AM EST

TONIX Pharmaceuticals Completes Pre-IND Meeting With FDA for Potential New Treatment for Post-Traumatic Stress Disorder

October 24, 2012 • 8:00 AM EDT

Tonix Pharmaceuticals Confirms Clinical Utility of TNX-102 Sublingual Tablet

October 23, 2012 • 8:00 AM EDT

Tonix Pharmaceuticals to Present at 2012 AEGIS Healthcare Conference

September 24, 2012 • 8:00 AM EDT

Tonix Pharmaceuticals Highlights Therapeutic Programs on CEONEWS.Tv

September 20, 2012 • 8:00 AM EDT

TONIX Pharmaceuticals Announces Poster Presentation at the 2012 American College of Rheumatology Annual Scientific Meeting

September 19, 2012 • 8:38 AM EDT

TONIX Pharmaceuticals' CEO Discusses the Company's New Treatment for Fibromyalgia on News-Medical.net

September 6, 2012 • 8:00 AM EDT

TONIX Pharmaceuticals to Present at Rodman & Renshaw 14th Annual Global Investment Conference on September 11

September 5, 2012 • 8:00 AM EDT

Tonix Pharmaceuticals' CEO Highlights Connection Between Disturbed Sleep and New Treatment for Fibromyalgia and Post-Traumatic Stress Disorder on KIDELA TV

August 27, 2012 • 8:00 AM EDT

Tonix Pharmaceuticals Issues Letter to Shareholders

August 21, 2012 • 8:00 AM EDT

Tonix Pharmaceuticals CEO Dr. Seth Lederman Describes Potential Treatment for Fibromyalgia, Post-Traumatic Stress Disorder and Traumatic Brain Injury

August 16, 2012 • 8:00 AM EDT

Tonix Pharmaceuticals Reports That Sublingual Formulation of Fibromyalgia Drug Reduces Production of a Psychoactive Metabolite, Improving Suitability for Long-Term, Chronic Treatment

August 14, 2012 • 8:00 AM EDT

Tonix Pharmaceuticals Announces Completion of Clinical Trial of Sublingual TNX-102

July 30, 2012 • 8:00 AM EDT

Tonix Pharmaceuticals Reports Positive Preclinical Data on Sublingual TNX-102

July 9, 2012 • 8:00 AM EDT

Tonix Pharmaceuticals to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28

June 27, 2012 • 11:00 AM EDT

Tonix Pharmaceuticals Receives Health Canada Clearance to Study a Novel Treatment for Fibromyalgia

June 27, 2012 • 8:00 AM EDT

Tonix Pharmaceuticals to Present at Marcum MicroCap Conference

June 19, 2012 • 8:00 AM EDT

Tonix Pharmaceuticals Featured on GLX-TV OpenCEOLive Series

June 14, 2012 • 8:00 AM EDT

Tonix Pharmaceuticals CEO Interviewed on CEOLive.TV

May 23, 2012 • 8:00 AM EDT

CORRECTING and REPLACING Tonix Pharmaceuticals Appoints Dr. Samuel Saks to Its Board of Directors

May 10, 2012 • 9:32 PM EDT

TONIX Pharmaceuticals to Present at Three Investor Conferences in May

April 30, 2012 • 6:11 AM EDT

TONIX Pharmaceuticals Completes Pharmacokinetic Study on New Formulation of TNX-102 for Fibromyalgia

April 5, 2012 • 5:40 PM EDT

TONIX Pharmaceuticals Strengthens Management Team with the Appointments of Its New Chief Financial Officer and Senior Director of Drug Development

April 4, 2012 • 6:04 AM EDT

TONIX Pharmaceuticals Holding Corp. Closes on Net Proceeds of $2.0 Million in Second Tranche of a $6.6 Million Private Placement

March 6, 2012 • 6:04 AM EST

TONIX Pharmaceuticals to Present at the 14th Annual Bio CEO & Investor Conference on February 14, 2012

February 7, 2012 • 6:01 AM EST

TONIX Pharmaceuticals Closes $4.3 Million Private Placement

January 23, 2012 • 6:05 AM EST

Tonix Pharmaceuticals to Present at Biotech Showcase and OneMedForum Conferences in San Francisco on January 9 and 10, 2012

January 4, 2012 • 6:05 AM EST

TONIX Pharmaceuticals to Present at the New York Society of Security Analysts’ 15th Annual Biotech and Specialty Pharmaceuticals Conference on November 30, 2011

November 21, 2011 • 6:05 AM EST

Tonix Pharmaceuticals Receives FDA Clearance to Initiate a Pharmacokinetic Study of TNX-102 For Fibromyalgia

November 18, 2011 • 7:30 AM EST

Tamandare Explorations Inc. Announces Name Change to Tonix Pharmaceuticals Holding Corp.

October 20, 2011 • 9:00 AM EDT

TONIX Pharmaceuticals and Tamandare Explorations Announce Completion of Share Exchange Transaction and Private Placement

October 14, 2011 • 9:00 AM EDT

Tonix Pharmaceuticals' Bedtime Very Low Dose Cyclobenzaprine Study Featured in Journal of Rheumatology

September 7, 2011 • 9:00 AM EDT

Tonix Pharmaceuticals Elects Charles Mather to its Board of Directors

August 17, 2011 • 9:00 AM EDT

Tonix Pharmaceuticals Elects Harvey Moldofsky, M.D., to its Scientific Advisory Board

June 20, 2011 • 9:00 AM EDT

TONIX Pharmaceuticals Presents Findings on the Effects of Bedtime Very Low Dose (VLD) Cyclobenzaprine (CBP) on Symptoms and Sleep Physiology in Patients with Fibromyalgia Syndrome

June 16, 2011 • 9:00 AM EDT

TONIX Pharmaceuticals Reports Analysis of Phase 2a Study of Very Low Dosage Cyclobenzaprine in Fibromyalgia Syndrome (FMS)

November 9, 2010 • 9:00 AM EST

TONIX Pharmaceuticals Elects Ernest Mario, PhD, to its Board of Directors

November 8, 2010 • 9:00 AM EST